Des structures imprimées en 3D pourraient accélérer la thérapie par cellules CAR-T

Français

Des chercheurs ont développé des gels imprimés en 3D imitant les ganglions lymphatiques afin d'améliorer la production de cellules CAR-T pour le traitement du cancer. Cette approche a permis d'augmenter les taux de réussite et d'accélérer la croissance cellulaire par rapport aux méthodes standard. Elle pourrait contribuer à réduire les coûts et à élargir l'accès à cette thérapie dans le monde entier.

Le processus standard de fabrication des cellules CAR-T implique l'extraction de lymphocytes T chez un patient, leur modification génétique à l'aide d'un virus pour cibler le cancer, puis leur multiplication sur plusieurs semaines. Cette procédure peut coûter plus de 280 000 livres sterling par cycle et prend souvent jusqu'à un mois, ce qui en limite la disponibilité, en particulier dans les pays à faible revenu.

Articles connexes

3D cryo-expansion microscopy image of a killer T cell's immune synapse with a tumor cell, revealing nanoscale killing machinery organization.
Image générée par IA

Cryo-expansion microscopy captures 3D architecture of killer T cells at the immune synapse, including in human tumors

Rapporté par l'IA Image générée par IA Vérifié par des faits

Researchers from the University of Geneva and Lausanne University Hospital report they have visualized, in three dimensions and under near-native conditions, how cytotoxic T cells organize their killing machinery at the immune synapse. The work, published in Cell Reports, applies cryo-expansion microscopy to human T cells and to tumor tissue samples, providing nanoscale views intended to support immunology and cancer research.

Stiffening cancer cells boosts car t-cell therapy in mice

Researchers have found that making cancer cells stiffer can enhance the effectiveness of car t-cell therapy against aggressive tumors. In experiments with mice, the approach led to complete tumor disappearance in some cases. The findings were presented recently at a conference in London.

CAR-T cell therapy shows early promise for HIV control

Rapporté par l'IA

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Health

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Health

Fully human antibody blocks tumor growth and metastasis in preclinical models of aggressive prostate cancer

Health

FDA-approved drug shows promise against rare liver cancer

Silica nanoparticles eliminate prostate tumors in mice

Researchers at Weill Cornell Medicine have developed tiny silica nanoparticles that destroyed aggressive prostate cancer tumors in mice while boosting the immune system. The treatment led to complete remissions when combined with immunotherapy.

Caribou Biosciences presents car-t updates at healthcare conference

Rapporté par l'IA

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

lundi 13 juillet 2026 05h10

Cell therapy keeps four children alive years after brain cancer diagnosis

lundi 29 juin 2026 21h11

USC scientists create renewable supply of cancer-fighting cells

mardi 02 juin 2026 11h34

Protein found to limit CAR T-cell therapy effectiveness

vendredi 29 mai 2026 15h41

Virus injection halts pancreatic tumor growth in trial

lundi 25 mai 2026 18h52

McGill researchers use reversible drug approach to boost natural killer cells against hard-to-treat cancers

Ce site utilise des cookies

Nous utilisons des cookies pour l'analyse afin d'améliorer notre site. Lisez notre politique de confidentialité pour plus d'informations.
Refuser